



Congress of the Central European Diabetes Association

Budapest, 10-12 June, 2021

Thursday, 10th June

- 13:00 – 13:30** **Opening ceremony – Thomas Stulnig, President of CEDA; Peter Kempler, President of the Local Organizing Committee, President Elect of CEDA**
- 13:30 – 14:45** **New technologies in diabetes**
Chair: Michael Roden, Germany; Nebojsa Lalic, Serbia
- 13:30 – 13:50 Michael Roden, Germany
Precision Diabetology - Novel Subtypes of Diabetes
- 13:50 – 14:10 Nebojsa Lalic, Serbia
The role of technology in diabetes treatment: glucose sensing in focus
- 14:10 – 14:30 Tomasz Klupa, Poland
"Do It Yourself" hybrid closed loop systems: challenges, risks and opportunities
- 14:30 – 14:45 Discussion
- 14:45 – 15:30** **State of the Art lecture**
Chair: Peter Kempler, Hungary; Thomas Stulnig, Austria
- Ferenc Oberfrank, Hungary
The dilemmas of medicine in the 21st century
- 15:30 – 16:00 COFFEE BREAK

- 16:00 – 17:40** **Clinical aspects of diabetes**
Chair: Maciej Malecki, Poland; Werner Waldhäusl, Austria
- 16:00 – 16:20 Dániel Végh, Hungary
Oral health and diabetes
- 16:20 – 16:40 Jan Skrha, the Czech Republic
Forty years of experience with insulinoma patients
- 16:40 – 17:00 Dénes Páll, Hungary
Treatment of hypertension in diabetes
- 17:00 – 17:20 Maciej Malecki, Poland
Treatment of diabetes mellitus in the elderly
- 17:20 – 17:40 Discussion
- 17:40 – 18:40** **Sanofi-Aventis symposium**

Friday, 11th June

- 8:15 – 10:30** **Diabetic neuropathy**
Chair: Peter Kempler, Hungary; Nicola Montano, Italy
- 8:15 – 8:35 Nikos Papanas, Greece
Praedibabetic neuropathy
- 8:35 – 8:55 Christian Herder, Germany
The role of inflammation in the pathogenesis of diabetic neuropathy
- 8:55 – 9:15 Nicola Montano, Italy
Autonomic Nervous System and Diabetes: the two sides of a coin
- 9:15 – 9:35 Tamás Várkonyi, Hungary
Gastrointestinal motility in diabetes – any connection between symptoms and findings?
- 9:35 – 9:45 Anna Körei, Hungary
Do we still need all five standard tests in the diagnosis of cardiovascular autonomic neuropathy?
- 9:45 – 10:05 Peter Kempler, Hungary
Pathogenetic oriented therapy of diabetic neuropathy
- 10:05 – 10:30 Discussion

10:30 – 11:00	COFFEE BREAK
11:00 – 12:40	Novo Nordisk symposium
12:40 – 13:50	LUNCH
13:50 – 15:05	COVID-related issues
	Chair: Manfredi Rizzo, Italy; Helmut Schatz, Germany
13:50 – 14:10	Anca Pantea Stojan, Romania <i>Death by SARS-CoV 2: a Romanian COVID-19 multi-centre comorbidity study</i>
14:10 – 14:30	Manfredi Rizzo, Italy <i>COVID-19, Diabetes and Obesity</i>
14:30 – 14:50	Helmut Schatz, Germany <i>Metformin, Raloxifen, Vitamin D for COVID-19?</i>
14:50 – 15:05	Discussion
15:05 – 15:30	COFFEE BREAK
15:30 – 17:10	Clinical sciences
	Chair: Nanette Schloot, Germany; Zdravko Kamenov, Bulgaria
15:30 – 15:50	Zdravko Kamenov, Bulgaria <i>Diabetes and menopause</i>
15:50 – 16:10	Gyula Petrányi, Cyprus <i>Polycystic ovary syndrome, insulin resistance, and metformin</i>
16:10 – 16:30	Nanette Schloot, Germany <i>New insights in type 1 diabetes: pathogenesis and prevention trials</i>
16:30 – 16:50	Angelo Avogaro, Italy <i>Therapeutic approaches to target both micro- and macrovascular disease in patients with type 2 diabetes</i>
16:50 – 17:10	Discussion

14:00 – 16:00 **Parallel poster sessions**
Chair: Tomasz Klupa, Poland; Jan Skrha, the Czech Republic

17:15 – 18:15 **Executive Committee Meeting**

Saturday, 12th June

8:30 – 9:30 **General Assembly**

9:30 – 10:30 **Boehringer-Ingelheim symposium**

10:30 – 11:00 COFFEE BREAK

11:00 – 12:40 **Cardiovascular risk in diabetes**

Chair: Thomas Stulnig, Austria; István Wittmann, Hungary

11:00 – 11:20 István Wittmann, Hungary
Risk of morbidity and mortality in patients with type 2 diabetes treated with sodium-glucose cotransporter-2 inhibitor and/or dipeptidyl peptidase-4 inhibitor: a nationwide study

11:20 – 11:40 György Jermendy, Hungary
Changes in trends of epidemiological data (incidence, prevalence, mortality) among people with pharmacologically treated T2DM between 2001 and 2016 in Hungary

11:40 – 12:00 Thomas Stulnig, Austria
Cardiovascular risk reduction in diabetes: are all needs met?

12:00 – 12:20 Erifili Hatziagelaki, Greece
The efficacy of new antidiabetic drugs beyond glucose regulation

12:20 – 12:40 Discussion

12:40 – 13:50 Light lunch